The impact of response kinetics for multiple myeloma in the era of novel agents-Reference-Cited by-同舟云学术

The impact of response kinetics for multiple myeloma in the era of novel agents

Published:2019-10-08 Issue:19 Volume:3 Page:2895-2904
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Yan Yuting¹,Mao Xuehan¹,Liu Jiahui¹,Fan Huishou¹,Du Chenxing¹,Li Zengjun¹,Yi Shuhua¹,Xu Yan¹,Lv Rui¹,Liu Wei¹,Deng Shuhui¹,Sui Weiwei¹,Wang Qi¹,Zou Dehui¹,Wang Jianxiang¹,Cheng Tao¹,Zhan Fenghuang²,Tai Yu-Tzu³,Yuan Chenglu⁴,Du Xin⁵,Qiu Lugui¹,Anderson Kenneth C.³,An Gang¹⁴⁵

Affiliation:

1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China;

2. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA;

3. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

4. Qilu Hospital of Shandong University (Qing dao), Qingdao, China; and

5. Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China

Abstract

Key Points Early responders with MM (TBR ≤3 months) are more likely to have higher lactate dehydrogenase levels and experience inferior outcomes. The kinetic pattern of response is a simple and powerful predictor for survival of patients with MM even in the era of novel agents.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/19/2895/1223953/advancesadv2019000432.pdf

Reference34 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

2. Association of response endpoints with survival outcomes in multiple myeloma;Lonial;Leukemia,2013

3. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?;Paiva;Clin Cancer Res,2015

4. Minimal residual disease in acute myeloid leukemia;Sung;Curr Treat Options Oncol,2017

5. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial;Zhu;Blood,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review;Frontiers in Oncology;2024-01-25

2. Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma;Therapeutic Advances in Medical Oncology;2024-01

3. The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma;2023-12-08

4. Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China;Hematology;2023-11-29

5. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma;Cancer;2023-10-17